

Firm News | July 26, 2021

Troutman Pepper's Private Equity and Venture Capital Practices Achieve New 2021 Q1 Industry League Table Rankings

RELATED PROFESSIONALS

[Christopher S. Miller](#) | [Thomas P. Dwyer](#) | [James E. Schutz](#)

NEW YORK – Troutman Pepper advised in more than one dozen funding rounds in Q1 2021 with an overall value of nearly \$500 million. Transactions spanned across both venture capital and LBO and related rounds.

“Last year’s merger added value and opportunity for our startup, early-stage high-growth clients,” said Partner Chris Miller who is one of the leaders of the firm’s Emerging Growth and Venture Capital Practice Groups. “Our [Startup and Early-Stage Entrepreneurial Development \(SEED\) Program](#) now caters to more than 200 active clients, and the uptick in the league tables captures part of that story.”

Troutman Pepper vaulted in the industry Refinitiv league table rankings, achieving recognition in five categories, including three in which it was previously unranked. Troutman Pepper also ranked in The Deal’s league table rankings, which it was previously unranked.

Refinitiv – Global Private Equity & Venture Capital Review Q1 2021

Venture Capital Rounds Legal Advisor to Company (Based on Round Value)

#12 ranked firm (unranked last year)

Venture Capital Rounds Legal Advisor to Firm (Based on Round Value)

#23 ranked firm (unranked last year)

Venture Capital Rounds Legal Advisor to Company (Based on Number of Rounds)

#10 ranked firm (unranked last year)

LBO & Related Rounds Legal Advisor to Company (Based on Number of Rounds)

#16 ranked firm (up from #38 last year)

All Rounds Legal Advisor to Company (Based on Number of Rounds)

#14 ranked firm (up from #48 last year)

The Deal Private Equity Law Firms 2021 Q1

#34 (unranked in 2020)

PitchBook's Q1 2021 Global League Tables (Based on Number of Deals)

Most Active in U.S.

#18 (unranked in 2020)

Most active in South

#9 (unranked in 2020)

Most active in Mid-Atlantic

#13 (unranked in 2020)

Most active in Southeast

#8 (unranked in 2020)

Most active in B2B

#14 (unranked in 2020)

Most active in B2C

#13 (unranked in 2020)

Most active in Representing U.S.: investors

#15 (unranked in 2020)

Troutman Pepper's SEED Program combines the resources of an experienced, multidisciplinary team into an affordable package for more than 200 startups, early-stage, and fast-growing companies. Clients receive legal counsel, mentoring, relationship building opportunities, and more.

The firm regularly advises startup, emerging growth and venture capital clients through every stage of their life cycle. Industries served span software, hardware and other high-technology, biotechnology, pharmaceuticals and medical devices, financial technology, healthcare, consumer products, food and beverage, media and telecommunications products and services, and many others.

Consistently recognized as a top-tier national practice, Troutman Pepper's corporate attorneys regularly handle multimillion- and multibillion-dollar transactions. Core areas of service include capital markets transactions and other significant domestic and cross-border transactions, mergers and acquisitions, corporate governance, securities laws compliance, and corporate finance. The firm has particular expertise in the private equity and private fund services space, advising clients on matters from fund formation to investments and exit transactions.

About Troutman Pepper

Troutman Pepper is a national law firm with more than 1,200 attorneys strategically located in 23 U.S. cities. The firm's litigation, transactional, and regulatory practices advise a diverse client base, from start-ups to multinational

enterprises. The firm provides sophisticated legal solutions to clients' most pressing business challenges, with depth across industry sectors, including construction, energy, finance, health sciences, insurance, private equity, real estate, and technology, among others. Learn more at troutman.com.

RELATED INDUSTRIES + PRACTICES

- [Corporate](#)
- [Emerging Companies + Venture Capital](#)
- [Health Care + Life Sciences](#)
- [Private Equity](#)